The common blood pressure medication named Losartan, also does not appear to have any significant harmful side effects on patients with COVID-19.
![Losartan May Not Reduce Hospitalization Due to COVID-19 Losartan May Not Reduce Hospitalization Due to COVID-19](https://images.medindia.net/health-images/1200_1000/singlecolour.jpg)
‘For patients with mild COVID-19, who do not require hospital admission, there is no use or harm from ACE inhibitors or angiotensin receptor blockers.’
Read More..
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
"Based on our results, there is no benefit to starting losartan for newly diagnosed outpatients with COVID-19, but those who are already taking the medication for pre-existing health conditions should feel safe continuing it," said Michael Puskarich, MD, an associate professor in the Department of Emergency Medicine at the U of M Medical School and co-principal investigator of this study. He is also an emergency physician at Hennepin Healthcare.Read More..
![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Some researchers believe losartan may reduce inflammation and help those infected recover, others worried that the drug could worsen COVID-19 symptoms.
"Given SARS-CoV-2 binding with ACE2 there has been significant research interest into the utility of ACE and AT1R blocking agents to combat COVID-19.
This study provides insight that for patients with mild COVID-19, who do not require hospital admission, that there is no benefit or harm from such agents," said co-principal investigator Christopher Tignanelli, MD, MS, an assistant professor in the Department of Surgery at the U of M Medical School and critical care surgeon with M Health Fairview.
The present research team is also working on other trial for inpatients to evaluate if losartan prevents lung injury in hospitalized patients with COVID-19 pneumonia. They have completed enrollment and are currently analyzing the data.
Advertisement
Source-Medindia